IFP Advisors
NTLA icon

IFP Advisors’s Intellia Therapeutics NTLA Stock Holding History

IFP Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18K Hold
1,492
– – ﹤0.01% 3019
2026
Q2 		$25.2K Sell
1,492
-6
-0.4% -$84 ﹤0.01% 2834
2026
Q1 		$19.2K Buy
1,498
+705
+89% +$8.98K ﹤0.01% 2802
2025
Q4 		$7.13K Sell
793
-3
-0.4% -$41 ﹤0.01% 3233
2025
Q3 		$13.7K Buy
+796
New +$9.8K ﹤0.01% 2753
2025
Q2 		– Sell
-202
Closed -$1.66K – 2776
2025
Q1 		$1.44K Buy
202
+181
+862% +$1.83K ﹤0.01% 3249
2024
Q4 		$245 Buy
+21
New +$328 ﹤0.01% 3638
2024
Q3 		– Sell
-1
Closed -$22 – 3402
2024
Q2 		$22 Buy
+1
New +$24 ﹤0.01% 3201
2023
Q3 		– Sell
-35
Closed -$1.43K – 3475
2023
Q2 		$1.43K Buy
+35
New +$1.42K ﹤0.01% 2979
2023
Q1 		– Sell
-228
Closed -$6K – 4084
2022
Q4 		$6K Sell
228
-50
-18% -$2.38K ﹤0.01% 3708
2022
Q3 		$22K Hold
278
– – ﹤0.01% 3003
2022
Q2 		$22K Hold
278
– – ﹤0.01% 2763
2022
Q1 		$22K Buy
278
+257
+1,224% +$21.8K ﹤0.01% 2760
2021
Q4 		$3K Buy
+21
New +$2.63K ﹤0.01% 2679
2019
Q4 		– Sell
-215
Closed -$2.99K – 3027
2019
Q3 		$3K Buy
+215
New +$3.43K ﹤0.01% 2558
2019
Q1 		$4K Sell
215
-1,000
-82% -$14.9K ﹤0.01% 1941
2018
Q4 		$16K Buy
1,215
+250
+26% +$4.65K ﹤0.01% 2253
2018
Q3 		$28K Sell
965
-915
-49% -$26.6K ﹤0.01% 2255
2018
Q2 		$51K Buy
1,880
+130
+7% +$3.15K ﹤0.01% 1893
2018
Q1 		$34K Hold
1,750
– – ﹤0.01% 2036
2017
Q4 		$34K Buy
1,750
+1,460
+503% +$33.7K ﹤0.01% 2061
2017
Q3 		$7K Buy
290
+50
+21% +$942 ﹤0.01% 3228
2017
Q2 		$4K Hold
240
– – ﹤0.01% 3516
2017
Q1 		$3K Hold
240
– – ﹤0.01% 3548
2016
Q4 		$3K Hold
240
– – ﹤0.01% 3527
2016
Q3 		$4K Buy
+240
New +$4.64K ﹤0.01% 3347

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Contrarius Group Holdings
Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

IFP Advisors's NTLA Position: Q3 2026 in Review

IFP Advisors held its Intellia Therapeutics (NTLA) position steady in Q3 2026 at 1,492 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #3019.

IFP Advisors first reported a position in NTLA in Q3 2016 and has held it in 26 quarters since. The position peaked at $51K in Q2 2018. 156 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • IFP Advisors held 1,492 shares of Intellia Therapeutics worth $18K as of Q3 2026.
  • IFP Advisors left its Intellia Therapeutics share count unchanged in Q3 2026.
  • Intellia Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3019 holding.
  • IFP Advisors first reported a position in Intellia Therapeutics in Q3 2016 and has held it in 26 quarters since.
  • IFP Advisors's Intellia Therapeutics position peaked at $51K in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.